These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 29587851)

  • 1. Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial.
    van der Heijde D; Sieper J; Maksymowych WP; Lambert RG; Chen S; Hojnik M; Anderson JK; Pangan AL
    Arthritis Res Ther; 2018 Mar; 20(1):61. PubMed ID: 29587851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study.
    Sieper J; Landewé R; Magrey M; Anderson JK; Zhong S; Wang X; Lertratanakul A
    RMD Open; 2019; 5(1):e000917. PubMed ID: 31245052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1).
    Sieper J; van der Heijde D; Dougados M; Mease PJ; Maksymowych WP; Brown MA; Arora V; Pangan AL
    Ann Rheum Dis; 2013 Jun; 72(6):815-22. PubMed ID: 22772328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Long-Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104-Week Results From a Randomized, Placebo-Controlled Study.
    Dougados M; van der Heijde D; Sieper J; Braun J; Citera G; Lenaerts J; van den Bosch F; Wei JC; Pedersen R; Bonin R; Jones H; Marshall L; Logeart I; Vlahos B; Bukowski JF; Maksymowych WP
    Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1590-1598. PubMed ID: 28482137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study.
    Landewé R; Sieper J; Mease P; Inman RD; Lambert RG; Deodhar A; Marzo-Ortega H; Magrey M; Kiltz U; Wang X; Li M; Zhong S; Mostafa NM; Lertratanakul A; Pangan AL; Anderson JK
    Lancet; 2018 Jul; 392(10142):134-144. PubMed ID: 29961640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial.
    van der Heijde D; Baraliakos X; Hermann KA; Landewé RBM; Machado PM; Maksymowych WP; Davies OR; de Peyrecave N; Hoepken B; Bauer L; Nurminen T; Braun J
    Ann Rheum Dis; 2018 May; 77(5):699-705. PubMed ID: 29343510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis.
    van der Heijde D; Joshi A; Pangan AL; Chen N; Betts K; Mittal M; Bao Y
    Rheumatology (Oxford); 2016 Jan; 55(1):80-8. PubMed ID: 26316575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-radiographic axial spondyloarthritis patients without initial evidence of inflammation may develop objective inflammation over time.
    Baraliakos X; Sieper J; Chen S; Pangan AL; Anderson JK
    Rheumatology (Oxford); 2017 Jul; 56(7):1162-1166. PubMed ID: 28387855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Procollagen I N-terminal peptide correlates with inflammation on sacroiliac joint magnetic resonance imaging in ankylosing spondylitis but not in non-radiographic axial spondyloarthritis: A cross-sectional study.
    Li X; Liang A; Chen Y; Lam NS; Long X; Xu X; Zhong S
    Mod Rheumatol; 2022 Jul; 32(4):770-775. PubMed ID: 34897520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial.
    Sieper J; Landewé R; Rudwaleit M; van der Heijde D; Dougados M; Mease PJ; Braun J; Deodhar A; Kivitz A; Walsh J; Hoepken B; Nurminen T; Maksymowych WP
    Arthritis Rheumatol; 2015 Mar; 67(3):668-77. PubMed ID: 25470228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol.
    Maksymowych WP; Kumke T; Auteri SE; Hoepken B; Bauer L; Rudwaleit M
    Arthritis Res Ther; 2021 Oct; 23(1):274. PubMed ID: 34715908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis.
    Braun J; Baraliakos X; Hermann KG; Landewé R; Machado PM; Maksymowych WP; Davies O; Hoepken B; Nurminen T; Stach C; van der Heijde D
    RMD Open; 2017; 3(1):e000430. PubMed ID: 28848654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
    van der Heijde D; Dougados M; Landewé R; Sieper J; Maksymowych WP; Rudwaleit M; Van den Bosch F; Braun J; Mease PJ; Kivitz AJ; Walsh J; Davies O; Bauer L; Hoepken B; Peterson L; Deodhar A
    Rheumatology (Oxford); 2017 Sep; 56(9):1498-1509. PubMed ID: 28498975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MRI evidence of structural changes in the sacroiliac joints of patients with non-radiographic axial spondyloarthritis even in the absence of MRI inflammation.
    Maksymowych WP; Wichuk S; Dougados M; Jones H; Szumski A; Bukowski JF; Marshall L; Lambert RG
    Arthritis Res Ther; 2017 Jun; 19(1):126. PubMed ID: 28587658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural changes in the sacroiliac joint on MRI and relationship to ASDAS inactive disease in axial spondyloarthritis: a 2-year study comparing treatment with etanercept in EMBARK to a contemporary control cohort in DESIR.
    Maksymowych WP; Claudepierre P; de Hooge M; Lambert RG; Landewé R; Molto A; van der Heijde D; Bukowski JF; Jones H; Pedersen R; Szumski A; Vlahos B; Dougados M
    Arthritis Res Ther; 2021 Jan; 23(1):43. PubMed ID: 33514428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spinal inflammation in the absence of sacroiliac joint inflammation on magnetic resonance imaging in patients with active nonradiographic axial spondyloarthritis.
    van der Heijde D; Sieper J; Maksymowych WP; Brown MA; Lambert RG; Rathmann SS; Pangan AL
    Arthritis Rheumatol; 2014 Mar; 66(3):667-73. PubMed ID: 24574227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consistently Good clinical response in patients with early axial spondyloarthritis after 3 years of continuous treatment with etanercept: longterm data of the ESTHER trial.
    Song IH; Hermann KG; Haibel H; Althoff CE; Poddubnyy D; Listing J; Weiß A; Buß B; Freundlich B; Lange E; Alten R; Rudwaleit M; Sieper J
    J Rheumatol; 2014 Oct; 41(10):2034-40. PubMed ID: 25028375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial.
    Dougados M; van der Heijde D; Sieper J; Braun J; Maksymowych WP; Citera G; Miceli-Richard C; Wei JC; Pedersen R; Bonin R; Rahman MU; Logeart I; Wajdula J; Koenig AS; Vlahos B; Alvarez D; Bukowski JF
    Arthritis Rheumatol; 2014 Aug; 66(8):2091-102. PubMed ID: 24891317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Course of Magnetic Resonance Imaging-Detected Inflammation and Structural Lesions in the Sacroiliac Joints of Patients in the Randomized, Double-Blind, Placebo-Controlled Danish Multicenter Study of Adalimumab in Spondyloarthritis, as Assessed by the Berlin and Spondyloarthritis Research Consortium of Canada Methods.
    Pedersen SJ; Poddubnyy D; Sørensen IJ; Loft AG; Hindrup JS; Thamsborg G; Asmussen K; Hendricks O; Nørregaard J; Piil AD; Møller JM; Jurik AG; Balding L; Lambert RG; Sieper J; Østergaard M
    Arthritis Rheumatol; 2016 Feb; 68(2):418-29. PubMed ID: 26414004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis.
    Sieper J; van der Heijde D; Dougados M; Maksymowych WP; Scott BB; Boice JA; Berd Y; Bergman G; Curtis S; Tzontcheva A; Huyck S; Weng HH
    Arthritis Rheumatol; 2015 Oct; 67(10):2702-12. PubMed ID: 26139307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.